Multiple Sclerosis Journal-Experimental Translational and Clinical
Scope & Guideline
Connecting Experimental Discoveries with Clinical Applications
Introduction
Aims and Scopes
- Clinical Effectiveness and Safety of Treatments:
The journal focuses on the clinical effectiveness and safety of various disease-modifying therapies, including novel and established treatments for relapsing and progressive forms of multiple sclerosis. - Biomarkers and Diagnostic Tools:
There is a significant emphasis on identifying and validating biomarkers for MS, which can aid in diagnosis, prognosis, and monitoring treatment responses. - Patient-Centered Care and Quality of Life:
Research exploring the impact of MS on patients' quality of life, including psychosocial factors, fatigue, and cognitive function, is a core area of interest. - Epidemiological and Health Services Research:
The journal publishes studies that investigate the epidemiology of MS, healthcare utilization, and the socioeconomic impact of the disease on patients and healthcare systems. - Innovative Therapeutic Approaches:
The journal is open to innovative therapeutic approaches, including cognitive rehabilitation, lifestyle interventions, and the integration of technology in MS management.
Trending and Emerging
- Pediatric Multiple Sclerosis Research:
There is an increasing focus on pediatric multiple sclerosis, exploring unique clinical characteristics, treatment responses, and the impact of MS on children and adolescents. - Real-World Evidence and Comparative Effectiveness Research:
The trend towards real-world evidence is growing, with studies comparing treatment outcomes in everyday clinical practice rather than controlled trials, providing insights into the effectiveness of therapies in diverse populations. - Cognitive Rehabilitation and Mental Health Interventions:
Emerging research is highlighting the importance of cognitive rehabilitation and mental health interventions to improve the overall well-being of MS patients, indicating a holistic approach to disease management. - Impact of COVID-19 on MS Patients:
Research focusing on the implications of COVID-19 for individuals with MS, including vaccine responses and the management of disease during the pandemic, has become increasingly relevant and prevalent. - Technology-Enhanced Monitoring and Treatment:
There is a growing interest in technology-enhanced solutions for monitoring disease progression and treatment adherence, including the use of wearables and telehealth solutions.
Declining or Waning
- Traditional Pharmacological Interventions:
There seems to be a waning focus on traditional pharmacological interventions without new mechanisms or innovative delivery systems, as more studies lean towards novel therapies and personalized medicine. - Animal Models of MS:
Research emphasizing animal models of MS has decreased, possibly due to the growing emphasis on human-centric studies that better reflect patient experiences and outcomes. - Single-Symptom Focus Studies:
There has been a decline in studies that focus solely on single symptoms of MS, such as fatigue or pain, as the trend shifts towards more holistic approaches that consider multiple aspects of MS.
Similar Journals
Archives of Neuroscience
Championing academic excellence in neuroscience exploration.Archives of Neuroscience is a multidisciplinary journal dedicated to advancing the field of neuroscience through the publication of original research articles, review papers, and case studies. Published by BRIEFLAND, this journal aims to bridge the gap between neuroscience research and clinical applications, fostering a deeper understanding of brain function, neurological disorders, and potential therapeutic approaches. With an ISSN of 2322-3944 and an E-ISSN of 2322-5769, Archives of Neuroscience serves as an essential platform for researchers, professionals, and students alike, encouraging open access to knowledge and insights that drive innovation in the field. Although coverage was discontinued in Scopus from 2016 to 2017, the journal continues to uphold rigorous standards of academic excellence, making it a valuable resource for the neuroscience community seeking to explore and disseminate new findings. The journal is committed to providing timely access to research tools and findings that are crucial for informed decision-making in both academic and clinical settings.
REVISTA DE NEUROLOGIA
Connecting Research and Clinical Practice in NeurologyREVISTA DE NEUROLOGIA is a distinguished academic journal focusing on the broad fields of neurology and medicine, published in Spain since its inception in 1959. The journal plays a vital role in disseminating significant research findings, clinical studies, and advancements in neurological science, catering to an audience of researchers, clinicians, and students alike. With an ISSN of 0210-0010 and an E-ISSN of 1576-6578, this quarterly publication has maintained its commitment to enhancing the understanding of neurological disorders and therapies through rigorous peer-reviewed articles. While currently not classified as open access, it is indexed in Scopus, holding a rank of #253 out of 400 in the category of Medicine (Neurology), reflecting its relevance in the field with a 36th percentile. The journal is positioned within the Q3 quartile for both Medicine (miscellaneous) and Clinical Neurology categories as of 2023. Based in Barcelona, Spain, it is a vital resource for anyone devoted to the advancement of knowledge and practice in neurology.
Multiple Sclerosis and Related Disorders
Unraveling the complexities of multiple sclerosis and beyond.Multiple Sclerosis and Related Disorders, published by Elsevier Science Ltd, is a leading journal that serves as a vital resource in the field of neurology, particularly focused on multiple sclerosis and its associated conditions. This esteemed journal, which holds a Q1 ranking in Medicine (miscellaneous) and Q2 ranking in both Neurology and Clinical Neurology, delivers high-impact research findings and clinical insights crucial for advancing the understanding and management of multiple sclerosis. With an ISSN of 2211-0348 and an E-ISSN of 2211-0356, it provides valuable content from 2012 to 2024 aimed at researchers, healthcare professionals, and students dedicated to improving patient outcomes and fostering innovative strategies in treatment. Additionally, the journal's presence in the Scopus rankings highlights its relevance and influence in the academic community, ranking 121 out of 400 in Clinical Neurology and 59 out of 192 in Neuroscience. This comprehensive platform encourages the dissemination of cutting-edge knowledge and clinical practices, making it an essential tool for those committed to the field of neurology and related research.
Neurology International
Empowering Knowledge in Neurological DisordersNeurology International is a prestigious open-access journal published by MDPI that has been making significant contributions to the field of neurology since its establishment in 2009. With its ISSN 2035-8377, this journal is committed to disseminating high-quality, peer-reviewed research that addresses a wide range of clinical topics in neurology. Operating out of Basel, Switzerland, the journal holds a respectable Q2 ranking in the clinical neurology category as of 2023, indicating its influence and dedication to advancing scientific knowledge. Researchers and practitioners alike will find value in its comprehensive articles, which are readily accessible to a global audience, facilitating the sharing of innovative findings and clinical practices. As it converges towards 2024, Neurology International continues to provide a vital platform for scholarly discourse, aiming to improve patient outcomes and enhance our understanding of neurological disorders.
Journal of Scleroderma and Related Disorders
Empowering researchers to transform autoimmune disorder understanding.Journal of Scleroderma and Related Disorders, published by SAGE Publications Ltd, stands as a key platform dedicated to advancing the understanding of scleroderma and related autoimmune disorders. With its ISSN of 2397-1983 and E-ISSN of 2397-1991, this esteemed journal has been contributing to the field since its inception in 2016 and continues to attract attention with its convergence period extending to 2024. The journal operates with an open access policy, thus enhancing the visibility and accessibility of research findings for healthcare professionals, researchers, and students worldwide. Recognized for its significant impact, it holds a Q3 quartile ranking in Immunology and Q2 rankings in Immunology and Allergy and Rheumatology in 2023, showcasing its relevance in these critical fields. Furthermore, the journal has achieved commendable Scopus rankings, positioning it firmly within the top echelons of its categories, particularly in Medicine - Rheumatology (#33/73, 55th percentile). With its comprehensive scope, the Journal of Scleroderma and Related Disorders plays a pivotal role in disseminating vital research that can influence treatment strategies and improve patient care for those suffering from scleroderma and its related conditions.
Degenerative Neurological and Neuromuscular Disease
Fostering collaboration for a healthier nervous system.Degenerative Neurological and Neuromuscular Disease is a distinguished academic journal published by DOVE MEDICAL PRESS LTD, focusing on the latest advancements in the field of neurology and neuromuscular disorders. With a commitment to disseminating high-quality research, the journal aims to provide a critical platform for researchers, healthcare professionals, and students to share and engage with groundbreaking studies that advance our understanding of degenerative conditions affecting the nervous system. Although the journal's impact factor and h-index are currently not available, its open access model ensures that the valuable findings published within are accessible to a global audience, thereby fostering collaboration and innovation in neurological health. The journal's address is PO BOX 300-008, Albany, Auckland 0752, New Zealand, reflecting its international relevance and commitment to advancing the field of neurology. As the understanding of neurodegenerative diseases and neuromuscular challenges continues to evolve, Degenerative Neurological and Neuromuscular Disease serves as an essential resource for anyone dedicated to improving patient outcomes and advancing scientific knowledge.
Current Journal of Neurology
Transforming discoveries into clinical applications.Current Journal of Neurology, published by Tehran University of Medical Sciences, is an esteemed Open Access journal dedicated to advancing the field of neurology. Since its inception in 2011, the journal has provided a platform for innovative research and critical discourse in neurology and clinical neurology, with a focus on the latest advancements and methodologies. Although the journal currently holds a Q4 quartile ranking in both neurology and clinical neurology, its goal is to foster the global dissemination of knowledge and ideas relevant to the complexities of neurological disorders. Researchers, professionals, and students exploring this dynamic field will find valuable insights, as the journal aims to bridge the gap between emerging research and clinical application. Based in Tehran, Iran, the Current Journal of Neurology welcomes contributions that enhance understanding and treatment of neurological conditions, thereby promoting evidence-based practices across the globe.
Journal of Central Nervous System Disease
Transforming research into solutions for CNS diseases.Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.
Journal of Neurologic Physical Therapy
Empowering Practitioners in Neurologic Physical TherapyJournal of Neurologic Physical Therapy, published by Lippincott Williams & Wilkins, stands as a premier resource in the field of physical therapy with a specific focus on neurology. With an ISSN of 1557-0576 and an E-ISSN of 1557-0584, this journal serves as a vital platform for researchers, practitioners, and students from 2004 to 2024, illustrating its commitment to advancing knowledge in neurologic rehabilitation. It holds a prestigious Q1 ranking in categories such as Physical Therapy, Sports Therapy, and Rehabilitation and Rehabilitation, alongside Q2 rankings in Geriatrics and Gerontology, Medicine (Miscellaneous), and Neurology (Clinical). With an impact factor that reflects its significance, the journal hosts comprehensive studies and clinical insights that propel practice and innovation in neurologic physical therapy. The content is designed to enhance understanding and skills, making it an indispensable resource for those dedicated to improving patient care and outcomes in this critical area of health.
Neurodegenerative Disease Management
Innovating Strategies for Neurodegenerative ChallengesNeurodegenerative Disease Management is a distinguished journal published by FUTURE MEDICINE LTD, focusing on the pivotal issues surrounding the management of neurodegenerative diseases. Since its inception in 2014, this journal has emerged as a significant resource within the fields of medicine and neurology, currently holding a respected position with a Q2 category ranking in Medicine (miscellaneous) and Q3 in Neurology (clinical) for 2023. With an ISSN of 1758-2024 and E-ISSN 1758-2032, the journal provides a platform for the dissemination of innovative research, clinical practices, and advancements in treatment strategies for conditions such as Alzheimer's, Parkinson's, and multiple sclerosis. The journal is particularly committed to enhancing knowledge sharing among researchers, health professionals, and students, contributing to the collective effort in combatting neurodegenerative diseases. Though not open access, its articles are meticulously curated to ensure high-quality, impactful contributions to the field, making it an essential reference for those engaged in neurology and related disciplines.